Mealey's (August 5, 2021, 9:25 AM EDT) -- PHILADELPHIA — Class representatives asked a federal judge in Pennsylvania on July 14 to deny a motion for summary judgment on remaining federal securities laws claims brought against a generic drug company and certain of its current and former senior executives because the evidence presented sufficiently shows not only that the defendants’ alleged representations concealing their involvement in an illegal price-fixing scheme with competitors were false but also that the defendants knew that those statements were false when they were made....